SA518400552B1 - مركبات فوسفوراميدات - Google Patents

مركبات فوسفوراميدات

Info

Publication number
SA518400552B1
SA518400552B1 SA518400552A SA518400552A SA518400552B1 SA 518400552 B1 SA518400552 B1 SA 518400552B1 SA 518400552 A SA518400552 A SA 518400552A SA 518400552 A SA518400552 A SA 518400552A SA 518400552 B1 SA518400552 B1 SA 518400552B1
Authority
SA
Saudi Arabia
Prior art keywords
cladribine
compounds
derivatives
phosphoramidate
phosphoramidate compounds
Prior art date
Application number
SA518400552A
Other languages
English (en)
Inventor
هوج جريفيث
ماجدالينا سلوسارسزيك
ميكالا سيربى
كريستوفير مكجوجان
Original Assignee
نوكانا بلس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوكانا بلس filed Critical نوكانا بلس
Publication of SA518400552B1 publication Critical patent/SA518400552B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

يتعلق هذا الاختراع بمشتقات كلادريبين derivatives of cladribine. تكون المركبات عبارة عن مشتقات فوسفوراميدات phosphoramidate derivatives حيث يكون شق فوسفوراميدات phosphoramidate moiety موضوع على مجموعة 3'-هيدروكسيل 3'-hydroxyl group من كلادريبين. يتعلق الاختراع أيضا بصيغ صيدلانية من مشتقات كلادريبين واستخدامها في طرق علاج. المركبات مفيدة في علاج السرطان treatment of cancer.
SA518400552A 2016-06-01 2018-11-29 مركبات فوسفوراميدات SA518400552B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds
PCT/GB2017/051549 WO2017207986A1 (en) 2016-06-01 2017-05-31 Phosphoramidate nucleoside derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
SA518400552B1 true SA518400552B1 (ar) 2021-12-08

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400552A SA518400552B1 (ar) 2016-06-01 2018-11-29 مركبات فوسفوراميدات

Country Status (26)

Country Link
US (2) US10906929B2 (ar)
EP (1) EP3464309B1 (ar)
JP (2) JP7025351B2 (ar)
KR (1) KR20190015353A (ar)
CN (1) CN109195981A (ar)
AU (1) AU2017273117B2 (ar)
BR (1) BR112018074961A2 (ar)
CA (1) CA3025440A1 (ar)
CL (1) CL2018003404A1 (ar)
DK (1) DK3464309T3 (ar)
EA (1) EA036409B1 (ar)
ES (1) ES2801448T3 (ar)
GB (1) GB201609601D0 (ar)
HR (1) HRP20200983T1 (ar)
HU (1) HUE051335T2 (ar)
IL (1) IL263121B (ar)
MX (1) MX2018014859A (ar)
MY (1) MY198880A (ar)
PH (1) PH12018502606A1 (ar)
PL (1) PL3464309T3 (ar)
PT (1) PT3464309T (ar)
SA (1) SA518400552B1 (ar)
SG (1) SG11201810018TA (ar)
SI (1) SI3464309T1 (ar)
WO (1) WO2017207986A1 (ar)
ZA (1) ZA201807652B (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
LT3464271T (lt) 2016-05-31 2020-09-10 Kalvista Pharmaceuticals Limited Pirazolo dariniai kaip plazmos kalikreino inhibitoriai
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CA3094958A1 (en) * 2018-03-09 2019-09-12 Medivir Aktiebolag Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309525A2 (en) * 2000-07-13 2003-05-14 Micrologix Biotech, Inc. Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
LT3447061T (lt) 2011-03-01 2022-01-25 NuCana plc Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
EP2697242B1 (en) * 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
KR102421929B1 (ko) 2014-06-25 2022-07-15 뉴카나 피엘씨 젬시타빈-전구 약물 함유 제제
IL291927A (en) * 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
EP3464309B1 (en) 2020-06-10
PT3464309T (pt) 2020-06-23
PH12018502606A1 (en) 2019-10-21
GB201609601D0 (en) 2016-07-13
MY198880A (en) 2023-10-02
AU2017273117A1 (en) 2018-12-06
EP3464309A1 (en) 2019-04-10
US20190375779A1 (en) 2019-12-12
WO2017207986A1 (en) 2017-12-07
EA036409B1 (ru) 2020-11-06
CL2018003404A1 (es) 2019-04-05
ZA201807652B (en) 2021-05-26
HRP20200983T1 (hr) 2020-12-11
ES2801448T3 (es) 2021-01-11
BR112018074961A2 (pt) 2019-03-12
KR20190015353A (ko) 2019-02-13
JP7025351B2 (ja) 2022-02-24
EA201892745A1 (ru) 2019-05-31
SI3464309T1 (sl) 2020-10-30
CA3025440A1 (en) 2017-12-07
PL3464309T3 (pl) 2020-10-19
AU2017273117B2 (en) 2021-02-04
HUE051335T2 (hu) 2021-03-01
DK3464309T3 (da) 2020-06-29
US10906929B2 (en) 2021-02-02
IL263121B (en) 2021-10-31
MX2018014859A (es) 2019-03-07
IL263121A (en) 2018-12-31
SG11201810018TA (en) 2018-12-28
US20210130387A1 (en) 2021-05-06
CN109195981A (zh) 2019-01-11
JP2019517510A (ja) 2019-06-24
JP2022051936A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
SA518400552B1 (ar) مركبات فوسفوراميدات
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
NZ752526A (en) Pyrrolobenzodiazepine conjugates
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
MD4733B1 (ro) Anticorpi anti-TIGIT
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
MX2018005872A (es) Profarmacos de acido nucleico.
MX2017009608A (es) Compuestos anticancerigenos.
MX2016005900A (es) Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
WO2019028309A1 (en) AZAINDOLES AND THEIR METHODS OF USE